CD274 and neoplasm: We confirmed that the association we observed in the atezolizumab arm was robust to inclusion of PD-L1 positivity in the tumor as a covariate, indicating the PRS was independently associated with survival in this trial (adjusted HR = 0.65, 95% CI 0.51–0.83 per unit normalized PRS, Supplementary Fig. 16).